Venture Firms Reduce Biotechnology Investment on FDA Risk
Venture capital firms are investing less in experimental drugmakers and medical device makers because of what they say are regulatory hurdles, a survey found.

When it comes to FDA product approvals, we just can t have it all
The title of Scott Gottlieb s Wall Street Journal article How the FDA could cost you your life is not only sensational, but misguided. I am no apologist for the FDA s poor execution, weak resources and lack of transparency; however, the agency s existence and culture are a direct response to what American [...]